Hemera Biosciences Raises $3.75 Million; Patent Issued for Treating Age-related Macular Degeneration
Hemera Biosciences today announced its Series A financing of $3.75 million and issuance of US patent 8,324,182 B2 on December 4, 2012 for treating age-related macular degeneration (AMD) with a human protein, soluble CD59 -- otherwise known as protectin.Human genetic studies and preclinical research have shown that alterations in complementa significant driver of inflammation-- play a key role in the development of both wet and dry AMD, said Adam Rogers, MD, one of the founders of Hemera. Precli...